ECFS 2016: Current Strategies for the Long Term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator Therapy

http://academiccme.com/wp-content/uploads/2016/08/910619-125-x-125.jpg

Course Information

Therapautic Area: Pulmonolgy
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: July 25, 2016- July 24, 2017

 

Program Overview

The content for this activity is based on the satellite symposium, “Current Strategies for the Long Term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator Therapy” that was presented at the 39th European Cystic Fibrosis Society Conference on June 10, 2016. The emergence of novel targeted agents, that directly correct CFTR loss function alleles, has created new treatment opportunities for patients with cystic fibrosis with advanced disease. Knowledge of the role of these agents in the clinical setting is quickly evolving and will require physicians stay acquainted with the latest data as well as evidence-based treatment guidelines in order to achieve optimized cystic fibrosis patient care. Ideally, after diagnosis, a personalized approach would be adapted and tailored to the patient through genome-informed medicine. However, due to the relative recentness of genomic-based therapeutics, physicians may have a limited knowledge base regarding these new treatment options and how to best incorporate these agents into patient management plans. Although cystic fibrosis is still largely regarded as a pediatric disease, the median survival for patients is 35 years of age. Consequently, pediatric-to-adult cystic fibrosis care programs would allow suitable preparation time for this transition and develop a standardized group of self-care and management skills.

 

Target Audience

Pulmonologists, Pediatricians, and other healthcare clinicians responsible for the care of patients with CF.

Educational Objectives

  1. Discuss the importance of newborn screening, accurate diagnosis, genomic evaluation, and early pharmacologic intervention.
  2. Analyze the current relevant and emerging clinical trial data.
  3. Develop strategies for the CFTR modulated treated patient accurate life-long assessment, monitoring, and management.

Faculty

elborn_headshotStuart Elborn, MD (Chair)
Professor of Respiratory Medicine
Dean, School of Medicine, Dentistry and Biomedical Science
Queen’s University of Belfast
Belfast, Northern Ireland, United Kingdom

 

Davies Head shotJane Davies, MD
Professor of Paediatric Respirology and Experimental Medicine
Imperial College London
Honorary Consultant in Paediatric Respiratory Medicine
Royal Brompton and Harefield NHS Foundation Trust
London, England, United Kingdom

 

Mall Headshot2.5Marcus A. Mall, MD
Professor of Pediatrics
Chairman, Translational Lung Research Center Heidelberg (TLRC)
Director, Department Translational Pulmonology
Head, Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center
University of Heidelberg
Director, German Center for Lung Research
Heidelberg, Germany      

Flume Head shotPatrick A. Flume, MD
Professor of Medicine and Pediatrics
Director, Adult Cystic Fibrosis Program
Medical University of South Carolina
Charleston, South Carolina, United States

 

 

Plant headshotBarry Plant, MD
Consultant Respiratory Physician
Director, Adult Cystic Fibrosis Centre
Cork University Hospital
Professor, Department of Medicine
Cork University Hospital
University College Cork
Wilton, Cork, Ireland


Registration



This CME activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

This Educational activity is co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

eocme acme logo